Table 3 Outcomes and predictors of included CPMs
|  | Overall N = 241 | Development n = 182 | External validation n = 59 |
|---|---|---|---|
Sarcoma entity | |||
 Osteosarcoma | 54 (22.4%) | 46 (25.3%) | 8 (13.6%) |
 Ewing sarcoma | 29 (12.0%) | 25 (13.7%) | 4 (6.8%) |
 Soft-tissue sarcoma | 61 (25.3%) | 21 (11.5%) | 40 (67.8%) |
 Chondrosarcoma | 26 (10.8%) | 19 (10.4%) | 7 (11.9%) |
 Leiomyosarcoma | 13 (5.4%) | 13 (7.1%) | 0 (0.0%) |
 Angiosarcoma | 10 (4.1%) | 10 (5.5%) | 0 (0.0%) |
 Liposarcoma | 8 (3.3%) | 8 (4.4%) | 0 (0.0%) |
 Rhabdomyosarcoma | 7 (2.9%) | 7 (3.8%) | 0 (0.0%) |
Outcomes | |||
 Overall survival | 101 (41.9%) | 81 (44.5%) | 20 (33.9%) |
 Cancer-specific survival | 70 (29.0%) | 56 (30.7%) | 14 (23.7%) |
 Distant metastasis | 14 (5.8%) | 10 (5.5%) | 4 (6.8%) |
 Local recurrence | 10 (4.1%) | 8 (4.4%) | 2 (3.4%) |
 Disease-free survival | 9 (3.7%) | 4 (2.2%) | 5 (8.5%) |
 Lung metastasis | 3 (1.2%) | 3 (1.6%) | 0 (0.0%) |
 Metastasis-free survival | 3 (1.2%) | 3 (1.6%) | 0 (0.0%) |
 Progression-free survival | 3 (1.2%) | 3 (1.6%) | 0 (0.0%) |
 Other | 28 (11.6%) | 14 (7.7%) | 14 (23.7%) |
Ten most included predictors | |||
 Age | 179 (74.3%) | 133 (73.1%) | 46 (78.0%) |
 Size | 149 (61.8%) | 116 (63.7%) | 36 (61.0%) |
 Grade | 103 (42.7%) | 71 (39.0%) | 32 (54.2%) |
 Surgery | 77 (32.0%) | 69 (37.9%) | 8 (13.6%) |
 Site | 71 (29.5%) | 58 (31.9%) | 13 (22.0%) |
 Stage | 61 (25.3%) | 56 (30.8%) | 5 (8.5%) |
 Sex | 41 (17.0%) | 34 (18.7%) | 7 (11.9%) |
 Chemotherapy | 39 (16.2%) | 33 (18.1%) | 6 (10.2%) |
 Histological type | 63 (26.1%) | 29 (15.9%) | 34 (57.6%) |
 Race | 24 (9.9%) | 21 (11.5%) | 3 (5.1%) |